Now showing items 1033-1052 of 3035

    • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. 

      Horne, HN; Chung, CC; Zhang, H; Yu, K; Prokunina-Olsson, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Fletcher, O; Johnson, N; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; Benitez, J; González-Neira, A; Anton-Culver, H; Neuhausen, SL; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Nevanlinna, H; Khan, S; Matsuo, K; Iwata, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, VM; Chenevix-Trench, G; Wu, AH; Ven den Berg, D; Smeets, A; Zhao, H; Chang-Claude, J; Rudolph, A; Radice, P; Barile, M; Couch, FJ; Vachon, C; Giles, GG; Milne, RL; Haiman, CA; Marchand, LL; Goldberg, MS; Teo, SH; Taib, NA; Kristensen, V; Borresen-Dale, AL; Zheng, W; Shrubsole, M; Winqvist, R; Jukkola-Vuorinen, A; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Czene, K; Darabi, H; Hollestelle, A; Martens, JW; Li, J; Lu, W; Shu, XO; Cox, A; Cross, SS; Blot, W; Cai, Q; Shah, M; Luccarini, C; Baynes, C; Harrington, P; Kang, D; Choi, JY; Hartman, M; Chia, KS; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Sangrajrang, S; Brennan, P; Slager, S; Yannoukakos, D; Shen, CY; Hou, MF; Swerdlow, A; Orr, N; Simard, J; Hall, P; Pharoah, PD; Easton, DF; Chanock, SJ; Dunning, AM; Figueroa, JD (2016-01)
      The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, ...
    • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. 

      Vigorito, E; Kuchenbaecker, KB; Beesley, J; Adlard, J; Agnarsson, BA; Andrulis, IL; Arun, BK; Barjhoux, L; Belotti, M; Benitez, J; Berger, A; Bojesen, A; Bonanni, B; Brewer, C; Caldes, T; Caligo, MA; Campbell, I; Chan, SB; Claes, KB; Cohn, DE; Cook, J; Daly, MB; Damiola, F; Davidson, R; Pauw, A; Delnatte, C; Diez, O; Domchek, SM; Dumont, M; Durda, K; Dworniczak, B; Easton, DF; Eccles, D; Edwinsdotter Ardnor, C; Eeles, R; Ejlertsen, B; Ellis, S; Evans, DG; Feliubadalo, L; Fostira, F; Foulkes, WD; Friedman, E; Frost, D; Gaddam, P; Ganz, PA; Garber, J; Garcia-Barberan, V; Gauthier-Villars, M; Gehrig, A; Gerdes, AM; Giraud, S; Godwin, AK; Goldgar, DE; Hake, CR; Hansen, TV; Healey, S; Hodgson, S; Hogervorst, FB; Houdayer, C; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jacobs, L; Jakubowska, A; Janavicius, R; Jaworska-Bieniek, K; Jensen, UB; John, EM; Vijai, J; Karlan, BY; Kast, K; Investigators, K; Khan, S; Kwong, A; Laitman, Y; Lester, J; Lesueur, F; Liljegren, A; Lubinski, J; Mai, PL; Manoukian, S; Mazoyer, S; Meindl, A; Mensenkamp, AR; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Olah, E; Olopade, OI; Ong, KR; Osorio, A; Park, SK; Paulsson-Karlsson, Y; Pedersen, IS; Peissel, B; Peterlongo, P; Pfeiler, G; Phelan, CM; Piedmonte, M; Poppe, B; Pujana, MA; Radice, P; Rennert, G; Rodriguez, GC; Rookus, MA; Ross, EA; Schmutzler, RK; Simard, J; Singer, CF; Slavin, TP; Soucy, P; Southey, M; Steinemann, D; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tea, MK; Teixeira, MR; Teo, SH; Terry, MB; Thomassen, M; Tibiletti, MG; Tihomirova, L; Tognazzo, S; van Rensburg, EJ; Varesco, L; Varon-Mateeva, R; Vratimos, A; Weitzel, JN; McGuffog, L; Kirk, J; Toland, AE; Hamann, U; Lindor, N; Ramus, SJ; Greene, MH; Couch, FJ; Offit, K; Pharoah, PD; Chenevix-Trench, G; Antoniou, AC (2016-01)
      Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We conducted fine-scale ...
    • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. 

      Shi, J; Zhang, Y; Zheng, W; Michailidou, K; Ghoussaini, M; Bolla, MK; Wang, Q; Dennis, J; Lush, M; Milne, RL; Shu, XO; Beesley, J; Kar, S; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Zhao, Z; Guo, X; Benitez, J; Beeghly-Fadiel, A; Blot, W; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Brinton, L; Broeks, A; Brüning, T; Burwinkel, B; Cai, H; Canisius, S; Chang-Claude, J; Choi, JY; Couch, FJ; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Droit, A; Dork, T; Fasching, PA; Fletcher, O; Flyger, H; Fostira, F; Gaborieau, V; García-Closas, M; Giles, GG; Grip, M; Guenel, P; Haiman, CA; Hamann, U; Hartman, M; Miao, H; Hollestelle, A; Hopper, JL; Hsiung, CN; Ito, H; Jakubowska, A; Johnson, N; Torres, D; Kabisch, M; Kang, D; Khan, S; Knight, JA; Kosma, VM; Lambrechts, D; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Le Marchand, L; Margolin, S; Marme, F; Matsuo, K; McLean, C; Meindl, A; Muir, K; Neuhausen, SL; Nevanlinna, H; Nord, S; Børresen-Dale, AL; Olson, JE; Orr, N; van den Ouweland, AM; Peterlongo, P; Choudary Putti, T; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Shen, CY; Hou, MF; Shrubsole, MJ; Southey, MC; Swerdlow, A; Hwang Teo, S; Thienpont, B; Toland, AE; Tollenaar, RA; Tomlinson, I; Truong, T; Tseng, CC; Wen, W; Winqvist, R; Wu, AH; Har Yip, C; Zamora, PM; Zheng, Y; Floris, G; Cheng, CY; Hooning, MJ; Martens, JW; Seynaeve, C; Kristensen, VN; Hall, P; Pharoah, PD; Simard, J; Chenevix-Trench, G; Dunning, AM; Antoniou, AC; Easton, DF; Cai, Q; Long, J (2016-09)
      Previous genome-wide association studies among women of European ancestry identified two independent breast cancer susceptibility loci represented by single nucleotide polymorphisms (SNPs) rs13281615 and rs11780156 at 8q24. ...
    • First evaluation of the feasibility of MLC tracking using ultrasound motion estimation. 

      Fast, MF; O'Shea, TP; Nill, S; Oelfke, U; Harris, EJ (2016-08)
      To quantify the performance of the Clarity ultrasound (US) imaging system (Elekta AB, Stockholm, Sweden) for real-time dynamic multileaf collimator (MLC) tracking.The Clarity calibration and quality assurance phantom was ...
    • A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. 

      Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; Barr, S; Van Tornout, JM; Jie, F; Sandhu, S; Tan, DS; Moreno, V; LoRusso, PM; Kaye, SB; Schöffski, P (2016-04-12)
      BACKGROUND: The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by ...
    • First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. 

      Dwivedi, RC; St Rose, S; Roe, JW; Chisholm, E; Elmiyeh, B; Nutting, CM; Clarke, PM; Kerawala, CJ; Rhys-Evans, PH; Harrington, KJ; Kazi, R (2011-03)
      BACKGROUND: Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking ...
    • A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection 

      Salehi-Reyhani, A; Kaplinsky, J; Burgin, E; Novakova, M; deMello, AJ; Templer, RH; Parker, P; Neil, MAA; Ces, O; French, P; Willison, KR; Klug, D (ROYAL SOC CHEMISTRY, 2011)
      We have developed a generic platform to undertake the analysis of protein copy number from single cells. The approach described here is ‘all-optical’ whereby single cells are manipulated into separate analysis chambers ...
    • First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. 

      Sessa, C; Shapiro, GI; Bhalla, KN; Britten, C; Jacks, KS; Mita, M; Papadimitrakopoulou, V; Pluard, T; Samuel, TA; Akimov, M; Quadt, C; Fernandez-Ibarra, C; Lu, H; Bailey, S; Chica, S; Banerji, U (2013-07)
      A phase I study was conducted with the primary objective of determining the maximum tolerated dose (MTD) of AUY922 in patients with advanced solid tumors. Secondary objectives included characterization of the safety, ...
    • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. 

      Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; Yanagitani, N; Horiike, A; Kitazono, S; Ohyanagi, F; Doi, T; Kuboki, Y; Kawazoe, A; Shitara, K; Ohno, I; Banerji, U; Sundar, R; Ohkubo, S; Calleja, EM; Nishio, M (2019-03)
      HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ...
    • First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. 

      Pollack, SM; Lu, H; Gnjatic, S; Somaiah, N; O'Malley, RB; Jones, RL; Hsu, FJ; Ter Meulen, J (2017-10)
      Effective induction of antitumor T cells is a pivotal goal of cancer immunotherapy. To this end, lentiviral vectors (LV) are uniquely poised to directly prime CD8 T-cell responses via transduction of dendritic cells in ...
    • A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

      Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; Kwak, EL; Macarulla Mercadé, T; Geuna, E; Jose de Miguel-Luken, M; Patel, C; Kuida, K; Sankoh, S; Westin, EH; Zohren, F; Shou, Y; Tabernero, J (2017-09-01)
      Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid ...
    • First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. 

      Tomasello, G; Valeri, N; Ghidini, M; Smyth, EC; Liguigli, W; Toppo, L; Mattioli, R; Curti, A; Hahne, JC; Negri, FM; Panni, S; Ratti, M; Lazzarelli, S; Gerevini, F; Colombi, C; Panni, A; Rovatti, M; Treccani, L; Martinotti, M; Passalacqua, R (2017-12-19)
      Background: Survival for patients with advanced gastroesophageal cancer (AGC) using standard treatment regimens is poor. EGFR overexpression is common in AGC and associated with poor prognosis. We hypothesized that increasing ...
    • A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. 

      Mateo, J; Ganji, G; Lemech, C; Burris, HA; Han, S-W; Swales, K; Decordova, S; DeYoung, MP; Smith, DA; Kalyana-Sundaram, S; Wu, J; Motwani, M; Kumar, R; Tolson, JM; Rha, SY; Chung, HC; Eder, JP; Sharma, S; Bang, Y-J; Infante, JR; Yan, L; de Bono, JS; Arkenau, H-T (2017-10-01)
      Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of ...
    • Five endometrial cancer risk loci identified through genome-wide association analysis. 

      Cheng, TH; Thompson, DJ; O'Mara, TA; Painter, JN; Glubb, DM; Flach, S; Lewis, A; French, JD; Freeman-Mills, L; Church, D; Gorman, M; Martin, L; Hodgson, S; Webb, PM; Attia, J; Holliday, EG; McEvoy, M; Scott, RJ; Henders, AK; Martin, NG; Montgomery, GW; Nyholt, DR; Ahmed, S; Healey, CS; Shah, M; Dennis, J; Fasching, PA; Beckmann, MW; Hein, A; Ekici, AB; Hall, P; Czene, K; Darabi, H; Li, J; Dörk, T; Dürst, M; Hillemanns, P; Runnebaum, I; Amant, F; Schrauwen, S; Zhao, H; Lambrechts, D; Depreeuw, J; Dowdy, SC; Goode, EL; Fridley, BL; Winham, SJ; Njølstad, TS; Salvesen, HB; Trovik, J; Werner, HM; Ashton, K; Otton, G; Proietto, T; Liu, T; Mints, M; Tham, E; Li, MJ; Yip, SH; Wang, J; Bolla, MK; Michailidou, K; Wang, Q; Tyrer, JP; Dunlop, M; Houlston, R; Palles, C; Hopper, JL; Peto, J; Swerdlow, AJ; Burwinkel, B; Brenner, H; Meindl, A; Brauch, H; Lindblom, A; Chang-Claude, J; Couch, FJ; Giles, GG; Kristensen, VN; Cox, A; Cunningham, JM; Pharoah, PD; Dunning, AM; Edwards, SL; Easton, DF; Tomlinson, I; Spurdle, AB (2016-06)
      We conducted a meta-analysis of three endometrial cancer genome-wide association studies (GWAS) and two follow-up phases totaling 7,737 endometrial cancer cases and 37,144 controls of European ancestry. Genome-wide imputation ...
    • Flexible Data Analysis Pipeline for High-Confidence Proteogenomics. 

      Weisser, H; Wright, JC; Mudge, JM; Gutenbrunner, P; Choudhary, JS (2016-12-02)
      Proteogenomics leverages information derived from proteomic data to improve genome annotations. Of particular interest are "novel" peptides that provide direct evidence of protein expression for genomic regions not previously ...
    • Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. 

      Forster, MD; Ormerod, MG; Agarwal, R; Kaye, SB; Jackman, AL (2007-11)
      The alpha-folate receptor (alpha-FR) is a folate transporter with restricted expression levels in normal tissues. It is over-expressed in several cancers, particularly epithelial carcinomas, including nonmucinous ovarian ...
    • Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin’s lymphoma 

      Hendry, L; Bowen, A; Matutes, E; Swansbury, J; Catovsky, D (TAYLOR & FRANCIS LTD, 2004-05)
      A regimen combining fludarabine, cyclophosphamide and mitoxantrone (FCM) was used to treat 29 patients with relapsed or refractory chronic lymphocytic leukemia (CLL, N= 24) and low-grade non-Hodgkin’s lymphoma (NHL, N= 5) ...
    • Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium-specific FAK-kinase dead mice 

      Aires Batista, Silvia (2017)
      Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, ...